<DOC>
	<DOCNO>NCT01780688</DOCNO>
	<brief_summary>The main goal exploratory study evaluate pharmacokinetic profile nicotine candidate modify risk tobacco product THS 2.1 conventional cigarette ( CC ) .</brief_summary>
	<brief_title>Exploratory THS 2.1 Nicotine Pharmacokinetics Safety Study</brief_title>
	<detailed_description>This 2-period 2-sequence cross-over clinical study intend explore profile nicotine uptake ( rate extent nicotine absorb associated variability ) healthy smoker switch ( CC ) THS 2.1 ( single ad libitum use ) compare smoker continue use CC , comparator . This study serve optimize blood sample schedule sample size estimation study . This study also provide preliminary information relationship nicotine absorption urge smoke/withdrawal symptom use THS 2.1 compare CC , well safety profile , relate use THS 2.1 . After screen , enrolled subject admit clinic 8 day . This study duration include 2 consecutive period . Each period consist 1 day single use product precede 24-hour nicotine deprivation , 1 day ad libitum product use . After leave clinic , subject follow safety period 7 day . This clinical study conduct compliance International Conference Harmonisation technical requirement registration pharmaceutical human use ( ICH Good Clinical Practice ) , Declaration Helsinki amend 2008 , applicable regulatory requirement .</detailed_description>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Subject sign informed consent form commencement study procedures Healthy Caucasian age 23 65 year Subject current smoker least 3 year ( base selfreporting biochemically verify ) , , last 4 week , smoke least 10 commercially available nonmentholated CC per day , plan make quit attempt within next 3 month As per Investigator judgment , subject participate study reason ( e.g . medical , psychiatric and/or social reason ) The subject medical condition require smoke cessation , clinically relevant disease / condition could interfere study participation and/or study result The subject participate clinical study within 3 month prior Screening Visit Pregnant lactate woman , woman childbearing potential , absence / refusal use acceptable method effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Modified risk tobacco product ( MRTP )</keyword>
	<keyword>Smoking</keyword>
	<keyword>Nicotine profile</keyword>
</DOC>